Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir DF versus tenofovir DF + emtricitabine for chronic hepatitis B
ACTRN12607000371493Phase 2Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial in Chronic Hepatitis B (CHB) comparing Tenofovir DF + placebo with Tenofovir DF + emtricitabine (2 arms). Primary endpoint: Virological suppression at Week 48. Planned start Jun 2007; status: not yet recruiting.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12607000371493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000371493.